CTD Holdings (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, posted its presentation from the annual Family Support and Medical Conference organized by the National Niemann-Pick Disease Foundation (NNPDF).
Key Quote: “Our data suggest that Trappsol®Cyclo™ is safe when administered intravenously at the doses we are using in our clinical trials, and our data show encouraging effects in addressing NPC symptoms, including ataxia, behavioral manifestations of the disease, and liver dysfunction. Our newest data, which have not been presented until now, suggest that the drug clears cholesterol from liver cells of NPC patients based on histological results: this is the first time that we have been able to visualize clearance of cholesterol in liver cells of NPC patients following intravenous administration of our drug.” – Dr. Sharon Hrynkow, Chief Scientific Officer and Senior Vice President for Medical Affairs
The Backstory: Niemann-Pick type C Disease (NPC) is a rare genetic disease affecting 1 in 100,000 live births globally. NPC affects every cell in the body due to the defect in the NPC protein which is responsible for cholesterol processing in the cell. Because of the NPC defect in this disease, cholesterol accumulates abnormally in every cell in the body, causing symptoms in the brain, liver, spleen, lung and other organs. NPC is ultimately a fatal disease. CTD supports three clinical trial programs using its proprietary cyclodextrin drug, Trappsol® Cyclo™, administered intravenously, in the United States, the United Kingdom, Sweden, Israel and Italy for the treatment of NPC. Both main trials are nearing completion of enrollment, and one extension study is active with a second extension study soon to be active.
Disclosure
CTD Holdings (CTDH) is a client of RedChip Companies, Inc. CTDH agreed to pay RedChip Companies, Inc. a monthly cash fee for RedChip investor awareness services and consulting services.
To read full newsletter and learn about other top small cap stocks
